Is the $74B Celgene buyout already forcing a reckoning among Bristol-Myers Squibb’s R&D partners?
A lengthy R&D update for CytomX’s pipeline review day included a brief note on a housecleaning at Bristol-Myers Squibb that cost the smaller biotech a partner on 3 of their allied programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
